Herantis Pharma

Herantis Pharma is a Finland-based clinical-stage biotechnology company focused on developing disease-modifying therapies to stop or reverse the progression of neurodegenerative diseases.

Equities

Equities by Sector

Sectors

Thematics

Latest

Edison explains: Cloud on the horizon – why NEXT is bearish on the UK

2025 climate review: How much progress have we made?

Edison explains: Scottish surge – Highlands and Islands of Scotland investment boom

Audiovisual

Latest

Aamal Company – equity proposition

Meet the healthcare analyst webinar: The CNS renaissance

Halyk Bank – executive interview

About Edison

About Edison

Careers

Herantis Pharma (HEL: HRTIS)

Latest Insights

Herantis Pharma — HER-096 clears Phase Ib, eyes Phase II

Herantis Pharma — H125 results reflect Phase Ib progress

Herantis Pharma — Last patient visit completed for Phase Ib

Herantis Pharma — Dedicated to disease modification for PD

Sector

Equity Analyst

Key Management

Research

VolitionRx – Decoding the DNA of cancer

ASCO 2023 key takeaways

Machine learning in drug development

Outlook for 2023: Biotechs remain central to novel drug development

Oncology ABCs (part four): Blood cancers (AML) – notable innovations

Cell and gene therapies

Drug delivery platforms

Oncology ABCs (part three) – thinking outside the box in women’s cancer

Neuroscience comeback

IPO apocalypse

Oncology ABCs (part two) – vaccines: niche no longer

ESG, moving beyond the box tick

Oncology ABCs (part one) – a small-cap biopharma prospectus series

Cannabinoid manufacturing – Innovative approaches to the production of cannabinoids

Artificial intelligence in drug discovery

Biosynthesis – Taking the cannabinoid market to new heights

Seven things every investor should know about SIGA technologies & biological weapons

Confidence renewed as new COVID-19 vaccines demonstrate protection against emergent strains and efficacy with a single-dose regimen

Edison Exhibits- antibiotic development

The next wave in AMD

The A-B-T of biosimilars- Explaining contemporary life science issues

Cannabinoid Therapies- The coming retail wave

Cannabinoid Therapies- Therapeutics turning a corner

Trial outcomes and value – Explaining contemporary clinical trial issues

Drug pricing – Market access and reimbursement

The diagnostics sector

ASCO 2017

Deutsche Börse Eigenkapitalforum 2014 Research Guide

Edison healthcare quarterly: A boost for allergy immunotherapy

ASX Spotlight Conference – London, 6 March 2014

ASX Small to Mid Caps Conference – London, 7 March 2013

Edison healthcare quarterly: Boom times for US biotech

Edison healthcare quarterly: Crisis? What crisis?

Edison healthcare quarterly: How to please some of the people some of the time